Back

MAIA gains Spain and Portugal approvals as THIO-104 targets 2027 survival analysis

Verifying
  • MAIA received Spanish and Portuguese approval to screen patients for the Phase 3 THIO-104 trial.
  • THIO-104 has enrolled 65 patients at 28 European and 10 Taiwanese sites.
  • MAIA targets 100 dosed patients by year-end 2026 and a 2027 interim analysis.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.